CCRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cross Country Healthcare Inc (CCRN) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock is undervalued with a positively skewed risk/reward profile, supported by recent analyst upgrades, improving EBITDA margin targets, and a strategic pivot to tech-enabled staffing. Despite the recent revenue decline, the company's financials show significant improvements in net income and EPS, indicating potential for recovery. The technical indicators and options data do not show any immediate red flags, making it a reasonable entry point for long-term investment.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 61.392, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot point of 9.618, with resistance at 10.025 and support at 9.211, showing limited downside risk.
Wedbush upgraded the stock to Outperform with a price target of $15, citing revenue stabilization and profitability recovery.
Benchmark also upgraded the stock to Buy with a $14 price target, highlighting improving demand for travel nurses and higher margin segments.
The company's strategic pivot to tech-enabled staffing and a debt-free balance sheet provide long-term growth potential.
Revenue dropped significantly by -23.61% YoY in Q4
No significant hedge fund or insider trading activity indicates a lack of strong institutional confidence.
No recent news or congress trading data to act as immediate catalysts.
In Q4 2025, revenue declined to $236.76M (-23.61% YoY), but net income improved significantly to -$82.93M (+2109.67% YoY), and EPS increased to -2.56 (+2033.33% YoY). Gross margin slightly improved to 18.65%. Despite revenue challenges, the company shows signs of operational improvement.
Analyst sentiment is positive. Wedbush upgraded the stock to Outperform with a $15 price target, citing a positively skewed risk/reward profile. Benchmark upgraded it to Buy with a $14 price target, highlighting an improving outlook. UBS raised its price target to $10, maintaining a Neutral rating.
